Lilly ups bid for ICOS, analysts shrug off negative story

12/18/2006 | Forbes

Eli Lilly increased its bid for ICOS Corp. from $2.1 billion to $2.3 billion, and Lilly says the boards of both companies have unanimously approved the revised merger. Analysts seemed unfazed by a negative newspaper report of Lilly's marketing of its Zyprexa drug, with one saying the allegations in the story "are fairly widely known."

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC